Pancreatic cancer has one of the lowest survival rates of all cancers. The mechanism underlying chemo-resistance of pancreatic cancer is not well understood. Our previous article reported that small molecule YM155 induced apoptosis in pancreatic cancer cells via activation of death receptor 5. In this study, we aim to continuously address death receptor 5-mediated apoptosis in chemo-resistant pancreatic carcinoma. We found that in comparison to paired pancreatic cancer tissues and adjacent normal tissues, five of the six cancer tissues had downregulated death receptor 5 and upregulated Bcl-xL. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL expression. Interestingly, pre-treatment with Bcl-xL inhibitor ABT263 reversed the insensitivity of panc-1 cells to lexatumumab or PF573228-induced apoptosis. Specific small interfering RNA-mediated gene silencing of Bcl-xL effectively sensitized pancreatic cancer cells to lexatumumab or PF573228-induced apoptosis. Furthermore, lexatumumab and PF573228 combination was shown to exhibit significant xenograft pancreatic tumor growth inhibition in SCID mice. Our data provide fundamental evidence to support the notion that lexatumumab and PF573228 co-treatment could be a potentially effective regime for patients with pancreatic cancer.
Introduction
Pancreatic cancer is terminal in most cases with less than 5% survival rate. 1, 2 To date, surgical resection is the most effective treatment option to cure this malignant tumor. Most cases are detected at a late stage and are unresectable due to metastasis. The majority of pancreatic cancer patients do not survive more than 1 year post diagnosis. 3, 4 Unfortunately, pancreatic cancer demonstrates a broad resistance to current conventional chem otherapeutic agents, which are administered with the aim of inducing tumor cell apoptosis. 5, 6 Therefore, new chemothera peutic strategies that sensitize pancreatic cancer cells to sec ondary drug treatment are required for success.
Focal adhesion kinase (FAK), a protein tyrosine kinase, is able to mediate signal transduction from extracellular matrix (ECM) to cells. It has been reported that FAK is involved in cell proliferation, survival, motility, and invasion via interac tion with integrin and growth factor receptors. 7, 8 Over whelming evidence has been compiled that identifies FAK as a key molecule conferring chemotherapeutic resistance to pancreatic cancers, and resistance is conferred by enhancing antiapoptotic properties in tumor cells. [9] [10] [11] A number of spe cific inhibitors of FAK have been developed. 12 Of all, PF573228 (PF) is well documented and characterized. 13 PF is able to inhibit FAK activity by blocking the phosphoryla tion of FAKTyr 397 and has been shown to induce apoptosis or growth inhibition in prostate metastatic (PC3) cells, human ovarian adenocarcinoma (SKOV3) cells, gemcitabine resistant pancreatic cancer (L3.6p1) cells, pancreatic cancer (FG) cells, and canine kidney epithelial (MDCK) cells. 14, 15 However, the antitumor effects of PF on chemoresistant pancreatic cancer cells are poorly known.
Lexatumumab (Lexa/HGSETR2) is a fully humanized agonistic monoclonal antibody (mAb) to the tumor necro sis factor-related apoptosisinducing ligand receptor 2 (TRAILR2/death receptor 5 (DR5)). 16, 17 It has been shown that Lexa specifically binds to DR5 and induces apoptosis in a number of tumor cell lines, including renal cell carcinoma (RCC), human myeloma cell lines (HMCLs), and malignant pleural mesothelioma (MPM). 18 Our previous data have shown that Lexa and cyclohex imide (CHX) in dualcombination treatment can induce apoptosis in hepatocellular carcinoma (HCC) cells via the upregulation reactive oxygen species (ROS) levels, with out generating apoptotic effects in normal liver cells. 19 The beneficial synergy between Lexa and PF chemotherapy in pancreatic cancer has not been determined to date.
The purpose of this study is to investigate how to use PF or Lexa to induce apoptosis in chemoresistant pancreatic cancer cell lines. We found deregulated expression of DR5 and BclxL in a majority of pancreatic cancer tissues when compared with adjacent normal pancreatic tissues. Our results show that the combination of Lexa and PF induces robust apoptosis in chemoresistant pancreatic cancer cells, whereas monotreatment with either Lexa or PF has no apoptotic toxicity. We show that inhibition of the anti apoptotic Bcl2 family protein BclxL can sensitize either Lexa or PF to induce apoptosis in pancreatic cancer cells.
Materials and methods

Materials
ABT263 and PF were purchased from Selleck Chemical (Houston, TX); anticleaved Caspase 8, anticleaved Caspase 3, antiBclxL, antiBcl2, antiBax, antiBad, antiFAK, antiMcl1, and antiDR5 primary antibodies were obtained from Cell Signaling Technology (Beverly, MA); the AnnexinV apoptosis detection kit was obtained from BD Bioscience (San Diego, CA). Hoechst 33258 and antiβactin were obtained from Sigma (St Louis, MO); goat antirabbit horseradish peroxidase (HRP)-conjugated secondary antibody and goat antimouse secondary anti body conjugated with HRP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Lexatumumab was kindly provided by Human Genome Science Inc. (Rockville, MD).
Cell culture and reagents
Human pancreatic cancer cell lines, Panc1 and AsPc1, were grown in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum (Sigma) and antibi otics (100 U/mL penicillin and 100 µg/mL streptomycin) at 37°C in 5% CO 2 .
Hoechst staining assay
Apoptosis was determined through nuclear morphology change. After treatment with different stimuli, cells were stained with Hoechst 33258 at 37°C for 10 min. Cell nuclear condensation was detected using an Olympus fluo rescent microscope (Tokyo, Japan). Apoptotic cell death ratio was assessed by the counting of apoptotic cells with condensed nuclei in six to eight randomly selected areas.
Fluorescence-activated cell sorting assay
Apoptosis was measured using the AnnexinV detection kit according to the manufacturer's instructions. Flow cytometric analysis was performed to monitor the green fluorescence of the fluorescein isothiocyanate (FITC)conjugated AnnexinV and the red fluorescence of DNA bound propidium iodide (PI). All data were analyzed using Cell Quest software (BD).
Western blotting assays
Cells were harvested and washed twice with sterile cold phosphatebuffered saline (PBS). The cell pellets were resus pended in lysis buffer containing Nonidet P40 (Cell Signaling Technology) and incubated on ice for 30 min. After centrifugation at 12,000g at 4°C for 15 min, the supernatant was transferred to a new tube and the protein concentration was determined. Equivalent samples (20 µg of protein) were subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) on 12% gels. The proteins were transferred to nitrocellulose membranes and probed with the indicated primary antibodies, followed by the appropriate secondary antibodies conjugated with HRP. Immunoreactive bands were detected using enhanced chemiluminescence (ECL; Pierce, Rockford, IL). The molecular sizes of the proteins detected were determined by comparison with pre stained protein markers (BioRad, Hercules, CA).
Small interfering RNA knockdown
Small interfering RNA (siRNA) knockdown was per formed as previously described. 20 Smartpool predesigned siRNA duplexes targeted against human BclxL messenger RNA (mRNA) were from Cell Signaling Technology. Cells were plated at a density of 1 × 10 5 cells/well in six well plates (BD Bioscience). Next day, cells were trans fected with 100 nM siRNA duplex mixtures for 24 h in the presence of lipofectamine RNAiMax (Invitrogen, Carlsbad, CA) according to the manufacturer's instruc tions. A nonspecific random siRNA (Cell Signaling Technology) was also transfected at the same concentra tion as control.
Tumor growth inhibition test
Mice were managed humanely in line with the criteria out lined in the "Guide for the Care and Use of Laboratory Animals" (NIH publication 8623, revised 1985). Eight weekold male SCID mice were divided into two groups. Each mouse (five per group) was inoculated subcutane ously at a dorsal flank site with 1 × 10 7 cells in PBS. Tumor volume was measured with calipers once every 3 days. When tumor volume reached 100 mm 3 , mice were admin istrated with PBS or Lexa + PF via tail vein injection every other day for a total of 15 days. The effect of drug treat ment on tumor growth was analyzed statistically with indi vidual group comparison and evaluated by Student's paired ttest by SPSS 15.0 (Chicago, IL).
Statistical analysis
The experiments were repeated in triplicate with consist ent results, and representative findings are shown. Statistical analysis was performed using Student's ttest analysis, with p values <0.05 considered significant.
Results
Dysregulation protein expression in pancreatic cancer tissues
To verify the mechanism underlying the resistance of pan creatic cancer cells to chemotherapy, paired malignant pancreatic tissues and adjacent relative normal pancreatic tissues were collected. We compared protein expressions between paired pancreatic cancer and adjacent normal pancreatic tissues. Paired tissues were processed for west ern blotting to analyze protein levels of FAK, DR5, BclxL, Bcl2, Mcl1, and Bax. As shown in Figure 1 , our data revealed that 83% (five of six) of malignant tissues had lower expression of DR5 when compared with adjacent normal tissues. Malignant tissues had higher expression of BclxL and Bax (83%, five of six) than adjacent normal tissues, while the other two proteins Bcl2 and Mcl1 did not show apparent difference between normal and cancer tissues. We observed that FAK was elevated in 50% (3three of six) cancer tissues. These data suggest that DR5 and BclxL were dysregulated and might be crucial in malig nant pancreas tissues.
PF sensitizes Lexa to induce apoptosis in pancreatic cancer cells
It has been reported that both Panc1 and AsPc1 cells are resistant to TRAILinduced apoptosis. [21] [22] [23] To determine whether the chemoresistance of Panc1 cells and AsPc1 cells is associated with DR5 dysregulated lower levels, cell lines were treated with dimethyl sulfoxide (DMSO) (Control), Lexa (1 µg/mL), PF (10 µM), or both Lexa and PF for 24 h (Panc1 cells) or 48 h (AsPC1 cells). Nuclear condensation or DNA fragmentation assays were per formed to measure apoptosis. Our data indicated that single treatment with either Lexa or PF did not induce apoptosis in Panc1 cells or AsPc1 cells. Interestingly, combination treatment triggered a robust apoptotic response in both cell lines as determined by nuclear condensation detected in a majority of cells (Figure 2(a) ). To further confirm the apop totic effects of Lexa and PF combination treatment, Panc1 cells were treated with Lexa, PF, Lexa and PF or not and fluorescenceactivated cell sorting (FACS) based on Annexin VPI double staining was performed to assess apoptosis ratio. Consistent with the nuclear condensation results, the combination of Lexa and PF induced cell death in >70% of pancreatic cancer cells (Figure 2(b) ).To assess the intracellular apoptotic events induced by combined treatment, Caspase 8 and Caspase 3 activation was exam ined by western blotting analysis to show cleaved bands; our data indicated that only combination treatment trig gered Caspase 8 and Caspase 3 activation as determined by detection of Caspase cleavage products (Figure 2(c) ). These data suggest that Lexainduced apoptosis can be activated in the presence of FAK inhibition by PF in resist ant pancreatic cancer cells.
Protein expression in PF and Lexa-treated pancreatic cancer cells
To determine the molecular pathways influencing the sen sitivity of pancreatic cancer cells to the combination treat ment, we examined protein expression of key components of the intrinsic and extrinsic apoptosis pathways. Western blotting analysis demonstrated that the addition of PF increased DR5 expression levels by up to 10fold (Figure 3 ). We observed that the combination treatment (PF 10 µM and Lexa 1 µg/mL) decreased the expression of BclxL protein by up to 7fold (Figure 3 ). The anti apoptotic Bcl2 and proapoptotic molecules Bax and Bad did not show any significant difference (Figure 3 ). These (c) Panc-1 cells or AsPc-1 treated with indicated conditions for 24 or 48 h were harvested, and cell lysates were prepared and subjected to western blotting analysis. Caspase 8 and Caspase 3 activation was evaluated through detection of cleaved bands with specific antibodies. β-Actin protein levels were assessed as loading controls for equal total protein amounts. Representative bands are shown, and every experiment was repeated three times.
data suggest that the activity of PF and Lexa may be medi ated by activating DR5 and decreasing BclxL.
Bcl-2 inhibitor ABT263 sensitizes Lexaand PF-induced apoptosis
BclxL inhibition could sensitize Survivin inhibitor YM155 to induce apoptosis in resistant HCC cells. 24 In this study, we found that BclxL was elevated in malignant tissues and downregulated by PF and Lexa cotreatment induced apoptosis. Therefore, to verify the roles of BclxL in chemotherapy, we first used ABT263 to inhibit BclxL activity. Cells were pretreated with sublethal ABT263 followed by Lexa or PF. As shown in Figure 4 (a) and (b), Lexa or PF induced significant apoptosis in the presence of ABT263. These data suggest that BclxL inhibition is very crucial to cause sensitivity converse to treatment with either Lexa or PF.
Bcl-xL knockdown sensitizes pancreatic cancer cells to Lexa/PF-induced apoptosis
To further ascertain the specific member, the Bcl2 family regulating chemoresistance, we used BclxLspecific siRNA to knockdown its expression. Our results indicated that BclxL siRNAmediated gene silencing was highly efficient as compared to the control random siRNA ( Figure 5(a) ). To show that reduction in BclxL expression is linked to chemoresistance and sensitivity to apoptosis, Lexa or PF were used to treat cells harboring random siRNA or BclxLspecific siRNA. Nuclear condensation assays demonstrated that BclxL knockdown sensitized pancreatic cancer cells to both Lexa and PF to induce apoptosis (Figure 5(b) and (c) ). To further verify that depletion of BclxL increased Lexa or PFinduced apop tosis, we assessed Caspase 8 and Caspase 3 cleavage acti vation. Western blotting analysis showed that upon Lexa or PF stimulation, significant cleaved Caspase 8 or Caspase 3 accumulated only in BclxL gene silencing cells ( Figure 5(d) ). These data suggest that BclxL activity inhi bition is indeed essential for the loss of chemoresistance in pancreatic cancer cells, enabling the induction of apop tosis by either Lexa or PF.
PF and Lexa combination inhibits tumor growth in vivo
To investigate the in vivo anticancer effects of PF and Lexa on pancreatic carcinoma, xenograft tumor derived from Panc1 cells were established in SCID mice. Briefly, 10 mice were injected with Panc1 cells to form xenograft tumors. One group (five mice) was treated with PBS buffer (control group) and the other group (five mice) was admin istrated with PF and Lexa together. The results showed that the control mice had developed much larger and more highly vascularized tumors than those mice treated with PF and Lexa (Figure 6(a) ). There was a significant differ ence in tumor mass with at least a 3fold decrease in PF and Lexatreated mice when compared with untreated con trol mice ( Figure 6(b) ). To verify the involvement of DR5 upregulation and BclxL downregulation in PF and Lexa combinationinduced tumor growth inhibition, tumor tis sues from control or treated group were processed for west ern blotting. Our data indicated that PF and Lexa cotreatment indeed was able to promote DR5 expression, while reduce BclxL in five randomly paired tissues ( Figure 6(c) ). To verify Lexa and PF combination treatment induced apoptosis in xenograft tumor inhibition, apoptotic marker protein Caspase 3 cleavage activation was meas ured. In comparison to control group, we found that cleaved Caspase 3 was increased in five Lexa and PF cotreated tumor tissues, but not in control groups. These data suggest that the combination could effectively inhibit malignant pancreatic tumor growth in vivo by inducing apoptosis.
Discussion
In this study, we first provide evidence to show that DR5 activation induced by DR5 agonist Lexa could not pro mote apoptosis in pancreatic cancer cells. Significant Figure 3 . Protein expression in Lexa, PF, or Lexa and PFtreated pancreatic cancer cells. Panc-1 cells were treated with or without Lexa (1 µg/mL), PF (10 µM), or pre-treated with PF (10 µM) followed by Lexa (1 µg/mL) for up to 24 h. Cells were harvested and cell lysates were prepared for western blotting. DR5, Bcl-xL, Bcl-2, Bax, and Bad expressions were detected with specific antibodies. β-Actin protein levels were assessed as loading controls for equal total protein amounts. Representative bands are shown, and every experiment was repeated three times. The relative intensity of immunoblot bands was analyzed by ImageJ software. apoptotic effects were observed when Lexa was used along with PF. BclxL downregulation appears to be critical to sensitize PF and Lexainduced apoptosis. This combina tion treatment of PF and Lexa exerts tumor growth inhibi tion in a xenograft pancreatic cancer mouse model.
It is well documented that pancreatic cancers are insen sitive to current pancreatic cancer agents including gem citabine, 25 TRAIL, 26 and a very promising FAK inhibitor PF. [27] [28] [29] Reports from different research groups have argued that multidrug resistance-associated protein 2 (MDRP2), 30 IAP family proteins, 31 RAF/ERK, 32 Akt/ mTOR, 33 heatshock protein 27 (HSP27), 34 PKC, 35 Wnt/ βcatenin, 36 and microRNAs 37 are involved in pancreatic cancer resistance. Therefore, it is important to define the intracellular molecular targets that may contribute to new therapies. In this study, we analyzed the proteins' expres sion in paired pancreatic cancer tissue and adjacent normal pancreatic tissues. Interestingly, we found that in a small cohort of six cancer patients, five of the six pancreatic tumor tissues had a lower DR5 expression than the adja cent nontumor pancreatic tissues, suggesting that DR5 mediated apoptosis pathway deregulation may be an important determinant in chemotherapy resistance of pan creatic cancer cells to TRAIL and contributes to the pro gression of metastasis. To rule out the possible involvement of DR5 in chemoresistance of pancreatic cancer, we used Lexa, a mAb that specifically binds to DR5 receptor to activate apoptosis. Lexa is currently in phase I/II clinical trials in patients with various advanced malignancies. 38 Here, we found that Panc1 and AsPc1 cells are resistant to Lexainduced apoptosis, suggesting that the DR5 mediated apoptosis signaling pathway does not function in these malignant cells. This is in accordance with previous reports that Panc1 and AsPc1 cells are not responsive to TRAILinduced apoptosis and Panc1 cells are resistant to Lexa. 23, 39 It has been reported that the majority of pancre atic cancers overexpress FAK and FAK activation was able to abrogate TRAILinduced apoptosis in a number of cancer types such as ovarian cancer 40 and colon cancer. 41 Consistently, our data also showed that 50% malignant tis sues had elevated FAK (Figure 1) . Therefore, to verify the involvement of FAK in the prevention of Lexainduced apoptosis in pancreatic cancer cells, we performed experi ments pretreating pancreatic cancer cells with the FAK specific inhibitor PF; pretreatment of cells was followed by treatment with Lexa. We found that sublethal doses of PF successfully reversed the insensitivity of Lexa, sug gesting that FAK inhibition is indeed critical for DR5 mediated cell death in these pancreatic cancer cells. Interestingly, we also observed that treatment with PF increased the expression of DR5, making Lexa the optimal partner in this combination treatment, as Lexa induces apoptosis by binding to DR5 to initiate the intrinsic pathway. This is in accordance with our recent report that DR5 increase induced by YM155 is crucial for chemother apyinduced apoptosis in Panc1 cells. 42 In this study, we also noticed that five of the six malig nant tissues exhibited much higher antiapoptotic BclxL expression, which may provide a possible explanation why these malignant cells are insensitive to chemotherapy such as Lexa or PF. We hypothesized that FAK inhibition may affect intracellular Bcl2 family proteins and sensitize can cer cells to Lexainduced apoptosis. As expected, we found distinct BclxL protein decrease (7fold) under the combi nation treatment (Lexa 1 µg/mL + PF 10 µM) suggesting BclxL expression loss induces chemotherapeutic sensitiv ity in pancreatic cancer cells. To confirm the notion that BclxL plays a key role in resistance of pancreatic cancer Figure 5 . Bcl-xL knockdown sensitizes pancreatic cancer cells to Lexa/PF-induced apoptosis. (a) Panc-1 cells were transfected with synthesized random siRNA (as control) and Bcl-xL-specific siRNA, and after 48 h post-transfection cells were subjected to western blotting analysis with Bcl-xL specific polyclonal antibody. β-Actin protein levels were assessed as loading controls for equal total protein amounts. Representative bands are shown, and every experiment was repeated three times. (b) Panc-1 cells transfected with random siRNA or Bcl-xL siRNA were treated or not with Lexa (1 µg/mL) or PF (10 µM) for 24 h. Then cells were stained with Hoechst 33258 to test apoptotic cell death (representative apoptotic cells are marked with white arrows). (c) Apoptotic ratio in Figure 5 (b) was determined by counting cells with apoptotic nuclei as described in section "Materials and methods." Data represent the mean values of three independent experiments (*p < 0.05). (d) Panc-1 cells treated as in Figure 5 (b) were harvested, and cell lysates were prepared and subjected to western blotting analysis. Caspase 8 and Caspase 3 activation was assessed by the detection of cleaved bands with specific antibodies recognizing cleaved Caspase 8 and Caspase 3. β-Actin protein levels were assessed as loading controls for equal total protein amounts. Representative bands are shown, and every experiment was repeated three times. cells, a specific inhibitor ABT263 was used to block Bcl2 family activity and then cells were treated with Lexa or PF. Surprisingly, we found that ABT263 effectively sensitized Panc1 cells to undergo apoptosis upon treatment with either Lexa or PF. This is consistent with studies that ABT263 for the enhancement of TRAILmediated cell kill ing of HCC cells by inhibition of Bcl2 activity 43 and death receptor-mediated apoptosis is regulated by Bcl2 pro and antiapoptotic protein balance. 44 Moreover, the siRNA mediated BclxL depletion experiments provided further evidence to show that BclxL activity is critical for protect ing cells against Lexa or PFinduced apoptosis ( Figure 5 ). Overall, these data suggest that BclxL overexpression may be not a rare event and may contribute to pancreatic cancer development and resistance to chemotherapy. Our findings also imply that pancreatic tumors may be suscep tible to treatment by BclxL activity inhibition.
The anticancer effects of this combination with PF and Lexa via inhibiting BclxL and activate DR5 are further confirmed in a mouse model burden with pancreatic can cer. Additionally, we observed that Caspase 3 was acti vated in samples synergistically administrated with Lexa and PF, suggesting that Lexa and PF cotreatment could induce apoptosis in vivo. Taken together, our findings imply that blockage of oncogene protein BclxL is indeed crucial for targeting apoptosis induced by chemotherapeu tics with either Lexa or PF. This could be developed to be used as part of a novel chemotherapy treatment in combi nation with surgical resection to improve patient survival in the future. 
